Advion BioServices (Ithaca, New York) announced the expansion of its existing LC–MS Biomarker Services Group, which was launched in 2008 to develop and deliver customized assays for peptide, amino acid, lipid, neurotransmitter, and nucleotide biomarkers.
Advion BioServices (Ithaca, New York) announced the expansion of its existing LC–MS Biomarker Services Group, which was launched in 2008 to develop and deliver customized assays for peptide, amino acid, lipid, neurotransmitter, and nucleotide biomarkers. According to the company, the expansion is in response to increased interest from pharmaceutical companies in the use of biomarkers as indicators of pharmacological response to drugs. The expansion includes an increase in staffing, Thermo Scientific and Applied Biosystems mass spectrometers, and liquid chromatography and automated liquid handling systems. LC–MS biomarker assays reportedly help pharmaceutical companies streamline later-phase clinical trials by enabling the use of fewer subjects or patients.
Advancing Bladder Cancer Research with Mass Spectrometry: A FeMS Interview with Marta Relvas-Santos
November 12th 2024LCGC International interviewed FeMS Empowerment Award winner Marta Relvas-Santos on her use of mass spectrometry to identify potential biomarkers and therapies for bladder cancer. She also shared insights on her work with FeMS and advice for fellow scientists.
Exploring The Chemical Subspace of RPLC: A Data-driven Approach
November 11th 2024Saer Samanipour from the Van ‘t Hoff Institute for Molecular Sciences (HIMS) at the University of Amsterdam spoke to LCGC International about the benefits of a data-driven reversed-phase liquid chromatography (RPLC) approach his team developed.